We are live on ! Find out more
ATOS icon

Atossa Therapeutics
ATOS

12 hedge funds and large institutions have $1.01M invested in Atossa Therapeutics in 2014 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

9% more funds holding

Funds holding: 11 → 12 (+1)

8% more capital invested

Capital invested by funds: $937K → $1.01M (+$72K)

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$50.6K
2
Wells Fargo
Wells Fargo
California
+$27.2K
3
Nomura Holdings
Nomura Holdings
Japan
+$19.4K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$7.78K
5
BIM
BlackRock Investment Management
Delaware
+$3.89K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$23K
2
Goldman Sachs
Goldman Sachs
New York
-$19.4K
3
Morgan Stanley
Morgan Stanley
New York
-$15.6K

ATOS Hedge Fund Activity: Q2 2014 in Review

12 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2014, worth a combined $1.01M — up 7.7% from $937K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ATOS positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Virtu KCG Holdings, adding an estimated $50.6K. The largest seller was Millennium Management, exiting entirely with an estimated $23K sold.

  • 12 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2014, up from 11 in Q1 2014.
  • Funds reported $1.01M of Atossa Therapeutics stock for Q2 2014, up 7.7% quarter-over-quarter.
  • 3 funds opened new Atossa Therapeutics positions in Q2 2014 and 2 closed out, a net change of +1 holder.
  • The largest Atossa Therapeutics buyer in Q2 2014 was Virtu KCG Holdings, an estimated $50.6K added.
  • The largest Atossa Therapeutics seller in Q2 2014 was Millennium Management, an estimated $23K sold.

Based on aggregated 13F filings for Q2 2014.